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Original Article
Inherited Bleeding Disorders—Experience
of a Not-for-Profit Organization in Pakistan
Shabneez Hussain, FCPS, MBBS1 , Shahida Baloch, PhD1,
Azra Parvin, BSc1, Akbar Najmuddin, MBBS2, Farhana Musheer, MBBS3,
Mubashra Junaid, MBBS4, Rab Nawaz Memon, MBBS5,
Fareeda Bhanbhro, MBBS6, Hayat Ullah, FCPS, MBBS7,
and Bushra Moiz, FCPS, MCPS, MBBS8
Abstract
Patient registry is a powerful tool for planning health care and setting groundwork for research. This survey reports a detailed
registry of inherited bleeding disorders (IBD) and their management at a not-for-profit organization in a developing country to
form the basis for planning development and research. We reviewed medical records of patients with IBD from 8 hemophilia
treatment centers of Fatimid Foundation located in various cities. Information collected included sociodemographic data, diag-
nostic tests, severity of hemophilia A and B, number of bleeding episodes per year, site and frequency of hemarthrosis, and
seropositivity for viral diseases. We analyzed 1497 patients from November 1, 2015, to April 30, 2016. There were 1296 (87%)
males and 201 (13%) females with a mean age of 24.5 (11) years (range, 6 months to 65 years). Hemophilia A constituted the bulk
of IBD (848, 57%) followed by vonWillebrand disease (172, 11%), hemophilia B (144, 10%), platelet function defect (106, 7%), and
rare bleeding disorders (70, 5%). Mucocutaneous bleeding (1144, 76%) and hemarthrosis (1035 patients, 69%) were the main
complications. There were 1026 (69%) patients who received only blood components for treatment of any bleeding episode while
the remaining 464 (31%) were on combination therapy (blood components and factor concentrate). Seroreactivity for hepatitis C
was frequent (28%), while hepatitis B (1%) and human immunodeficiency virus (0.01%) were less commonly seen. This study was
an important step toward a patient registry in a hemophilia treatment center in Pakistan. Hemophilia A is the most common
bleeding disorder and hepatitis C is the most frequent treatment-related complication.
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Introduction
Inherited bleeding disorders (IBD) include coagulation factor
deficiencies and platelet function defects (PFDs). The treat-
ment of coagulation factor deficiencies includes replacement
therapy such as clotting factor concentrates, transfusion of
fresh frozen plasma (FFP), cryoprecipitate (CP), and cryosu-
pernatant (CS), while platelet transfusions are required in
PFDs. Treatment complications such as inhibitors develop-
ment and platelet refractoriness require infusion of prothrom-
bin complex concentrates or factor eight-inhibitor-by pass
agents (FEIBA).
The management of IBD is a challenging task in developing
countries. Lack of diagnostic facilities, shortage of blood com-
ponents, high cost of clotting factor concentrates, and poor
infrastructure of hemophilia treatment centers are among the
main reasons. In order to assess the burden of IBD and to plan
health care, there is a need for a patient registry in organiza-
tions involved in managing patients with bleeding disorders.1
This was stressed upon during a joint meeting of World Health
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Organization and World Federation of Hemophilia (WFH) in
1997 in Geneva, Switzerland.2 Their report recommended that
identification and diagnosis of patients and their families with
hemophilia and related problems must be prioritized.
Pakistan is a developing country with an estimated popula-
tion of 193 million people and a low gross domestic product per
capita of US$4.3 The health budget is mainly spent on battling
infectious disease and preventing maternal morbidity. Keeping
this in view, the management of IBD on a governmental level
becomes difficult, and this is where the role of nongovernmen-
tal organizations (NGO) becomes important. A disease registry
in a rare disease is an important tool for advocacy. A major
drawback of an NGO is a lack of patient registry, an online
database system, and skilled staff to manage the registry. This
results in a lack of data sharing from the NGOs to the national
member organization responsible for managing and updating
patient registry at a national level leading to underreporting
with possible duplication of data.
Pakistan has submitted national data to the WFH annual
global survey of 2015 published in 2016. According to this
report from 113 countries, 1646 cases of IBD were reported
from Pakistan.4
Patients receive on-demand replacement therapy with either
blood components or plasma-derived clotting factor concen-
trates in Pakistan. As the country does not manufacture clotting
factor concentrates, these are therefore imported and are expen-
sive disallowing their prophylactic usage. There have been
local sporadic data on the epidemiology and clinical character-
istics of IBD from southern Pakistan.5,6 In this retrospective
review of registry data of a single NGO, we describe the demo-
graphics, diagnosis, and treatment of IBD in 8 hemophilia
treatment centers in Pakistan.
Materials and Methods
This was a cross-sectional study conducted by 8 centers of
Fatimid Foundation (FF) from November 1, 2015, to June 1,
2016. Fatimid Foundation is a not-for-profit network of hemo-
philia treatment centers located in 4 provinces of Pakistan. The
centers are located in Quetta (Balochistan Province), Peshawar
(Khyber Pakhtoon Khwa province), Lahore and Multan (Pun-
jab province), Karachi, Hyderabad, Khairpur, and Rashidabad
(Sindh province).
A data collection form developed by staff at the Karachi
center was used by staff at all of the hemophilia treatment
centers to collect data on patients diagnosed or suspected with
IBD. All patients either diagnosed with or suspected of having
an IBD were eligible for inclusion in the study. Data collected
included demographic information, laboratory data, diagnosis,
severity of hemophilia A (HA) and hemophilia B (HB), pres-
ence of inhibitors, type of von Willebrand disease (vWD),
infection status for human immunodeficiency virus (HIV),
hepatitis C virus (HCV), hepatitis B virus (HBV), type of treat-
ment received (either blood components and/or factor concen-
trates), and follow-up visits.
Bleeding history was documented by reviewing the patient’s
file and recording the various sites of any bleeding. For each
patient, the number of bleeds was counted for each event, that
is, the data were collected as number of bleeding episodes
rather than number of patients with bleeding events. Data on
joint disability, physiotherapy, and the use of any orthopedic
appliance were also collected on the form.
All patients clinically diagnosed with IBD were screened
through laboratory tests: bleeding time (BT; Ivy modified tem-
plate method), activated partial thromboplastin time (APTT),
prothrombin time (PT), and platelet count. Further testing
included mixing studies with aged serum or adsorbed plasma
for prolonged PT and APTT. A patient with a prolonged APTT
correcting with adsorbed plasma/aged serum was clinically
managed as HA and HB, respectively. Patients were clinically
managed as vWD if they have prolonged BT and APTT while
those with prolonged PT and APTT were managed as rare
bleeding disorders (RBDs). Patients with a significant bleeding
history and normal screening tests were further investigated
with Factor XIII quantitative assay or urea clot lysis. Females
with a low-factor VIII level without von Willebrand factor
(vWF): Ag or vWF: ristocetin cofactor (RCoF) levels were
managed as either carrier for HA or vWD. In case, no investi-
gations or any one screening test was performed, the patient
was considered as “undiagnosed.”
Platelet function defects were diagnosed when a patient
had a prolonged BT with a defective platelet aggregometry.
Factor assay (VIII, IX, I, II, V, X), vWF antigen (vWF:Ag)
level, vWF:RCoF, and platelet aggregation studies were per-
formed for confirmation, when available at a center. Patients
with confirmed diagnosis were diagnosed as mild, moderate,
or severe HA or HB if diagnostic factor level was more than
5% to 40%, 1% to 5%, and <1%, respectively. Factor assays
were performed by one-stage coagulometric method on Sys-
mex CA-600 with a measuring range extending from 1% to
100% of the normal.
If FV level was found to be deficient, then FVIII level was
also performed. Analysis of vWF:Ag was performed on Sys-
mex CA-600 by immunoturbidimetric method using Innovance
reagent (Siemens, Marburg, Germany). To differentiate type 1
from type 2 vWD, vWF:RCoF to vWF:Ag ratio of <0.7 was
used.7 Undetectable vWF:Ag and RCoF with very low FVIII
level (1-9 IU/dL) led to the diagnosis of type 3 vWD.7 Multi-
mer analysis, von Willebrand collagen binding activity, and
ristocetin-induced platelet aggregation were not performed due
to the nonavailability and cost constraints. Patients were
labeled as “presumed vWD” in the presence of bleeding man-
ifestation and inadequate laboratory data (low levels of vWFAg
and FVIII).
Treatment details were recorded by reviewing the past med-
ical record of the patient and recording any treatment (CP, CS,
platelets, and/or clotting factor concentrates) that the patient
had received at the hemophilia treatment center after registra-
tion. Patients were categorized into those who had been treated
only with blood components or only clotting factor concen-
trates and those who had received combination therapy.
2 Clinical and Applied Thrombosis/Hemostasis
Combination therapy is defined as those patients who had
received treatment clotting factor concentrates and blood com-
ponents to treat any bleeding episode.
The completed data collection forms from all the centers
were sent to the hematologist (S.H.) in Karachi center who
entered and analyzed the data using SPSS version 22 statistical
software (IBM, Armonk, New York). The data bank was saved
in the computer under lock and key to protect the confidenti-
ality of information. Quantitative data were given as mean
(standard deviation) when normally distributed and median
(interquartile range) for nonparametric data. This study was
conducted after ethical approval from institutional research
ethics committee.
Results
The total number of patients with IBD registered at various FF
centers is 1497, and the facilities provided to these patients by
the respective centers are shown in Table 1. The majority of
patients resided in Sindh province (800, 53%) followed by
Punjab (348, 23%), Khyber Pakhtoon Khwa (283, 19%), Balo-
chistan (59, 4%), Gilgit Baltistan (2, 0.1%), Azad Kashmir (2,
0.1%), and Afghanistan (3, 0.2%).
Clinical and Laboratory Diagnosis
The distribution of patients according to different age groups is
shown in Figure 1. Overall, inherited clotting factor deficiency
was seen in 1256 (84%) patients while 106 (7%) were diag-
nosed as PFD and the remaining 135 (9%) patients were
undiagnosed. As shown in Table 2, majority of registered
patients had HA (848, 57%), and vWD constituted next com-
mon IBD (172, 11%) followed by HB (144, 10%), rare bleeding
disorders (70, 5%), and suspected HA carrier/vWD (22, 1%)
patients. Mild, moderate, and severe forms of HA and HB were
seen in 19%, 34%, 47%, and 30%, 40%, 30% patients, respec-
tively. Type 1 and 3 vWD was diagnosed in 13 (16%) and 70
(84%) patients, respectively.
Factor V deficiency (15, 28%) was the most common RBD
followed by hypofibrinogenemia (12, 22%), FXIII deficiency
(8, 15%), and afibrinogenemia (6, 11%). Less frequent RBDs
include FVII (4, 7%), FX (4, 7%), combined FV and VIII
deficiency (4, 7%), and FII deficiency (1, 2%). There were
11 (73%) patients who had severe FV deficiency. Two patients
had a FVII activity of less than 1% while the remaining 2
patients had moderate deficiency. Severe FX deficiency was
present in 2 patients while the remaining 2 patients had mod-
erate and mild deficiency, respectively.
Glanzmann thrombasthenia (GTT; 74, 86%) was the most
common PFD followed by Bernard-Soulier syndrome (BSS;
10, 12%) and storage pool defect (2, 2%).
Demographics and Clinical Details
The demographics and clinical details of patients are summar-
ized in Table 2. The mean age (known for 1466 patients) at the
time of data collection was 24.5 (11) years (range, 6 months to
65 years), and there were 1296 (87%) males. The age at diag-
nosis of bleeding disorder was known for 1135 (76%)
patients. The median age at diagnosis was 6 years (range,
birth to 54 years). Majority of the individuals were either
pediatrics (1172, 88%) or adolescent (93 or 7%) when first
presented/diagnosed while 70 (5%) were adults. At the time of
data collection, young adults (19-44 years) constituted 65% of
registered patients.
Consanguinity was observed in 399/651 (61%) patients.
Seven hundred patients (47%) had a family history of bleeding,
while 84 (6%) family members of the registered patients died
Table 1. Summary of Diagnostic and Management Facilities Available at Each Center.a
Center
No. of Registered Patients Laboratory Facilities Treatment Facilities
Total Diagnosed
Clinical
Diagnosis Undiagnosed
Screening Tests
(PT, APTT,
Bleeding Time,
and Platelet
Count)
Diagnostic Tests
(Mixing Studies,
Factor Level,
and Inhibitor
Screening)
Screening
for HBV,
HCV,
& HIV
CP, CS &
Platelet FFP CFCb Physiotherapy
Karachi 735 510 (70) 201 (27) 24 (3) þ þ þ þ þ þ þ
Lahore 285 109 (38) 154 (54) 22 (8) þ 0 þ þ þ þ þ
Peshawar 289 44 (15) 199 (69) 46 (16) þ 0 þ þ þ þ 0
Quetta 44 4 (9) 10 (23) 30 (68) þ 0 þ 0 þ þ þ
Multan 46 23 (50) 9 (20) 14 (30) þ 0 þ þ þ þ þ
Hyderabad 58 33 (57) 21 (36) 4 (7) þ 0 þ þ þ þ 0
Khairpur 11 8 (73) 3 (27) 0 þ 0 þ þ þ þ 0
Rashidabad 29 25 (86) 4 (14) 0 0 0 þ þ þ þ 0
Total 1497 823 (55) 539 (36) 135 (9) – – – – – – –
Abbreviations: APTT, activated partial thromboplastin time; CFC, clotting factor concentrates; CP, cryoprecipitate; CS, cryosupernatant; FFP, fresh frozen plasma;
HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; PT, prothrombin time.
a“þ” Indicates present and “0” indicates absent.
bPlasma derived, available free of cost only in emergency setting.
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due to life-threatening bleeding. Hemoglobin level and red cell
indices performed within 3 months of data collection were
available for 1070 (71%) patients. Hypochromic and microcy-
tic anemia was diagnosed in 699 (65%) patients, and169 (24%)
patients were on iron replacement therapy. Laboratory tests for
assessment of storage iron were not available.
Bleeding Complications
The number of bleeding episodes per year is shown in Figure 2.
As shown in Table 2, mucocutaneous bleeding was the com-
monest symptom experienced by majority (76%) of the patients
during their lifetime. Menorrhagia was common in females
with vWD while bleeding during circumcision was predomi-
nant in vWD and HA.
Acute hemarthrosis was another frequent bleeding compli-
cation experienced by 1035 (69%) patients, mainly HA and
HB. However, it was also seen in patients with PFDs. Knee
joint (823, 80%) was the most common site of hemarthrosis
followed by elbow (474, 46%), ankle (412, 40%), shoulder
(244, 24%), hip (211, 20%), and wrist (96, 9%) joints. Joint
disability was present in 183 (18%) patients including 133
(73%) HA, 13 (7%) HB, 12 (7%) vWD, 5 (3%) RBD, 1
(0.5%) PFD, 2 (1%) HA carrier/vWD, and 17 (9%) undiag-
nosed patients. Knee joint (139, 76%) was the most commonly
affected followed by elbow (21, 12%), hip (14, 8%), ankle (13,
7%), and shoulder joints (4, 2%). Flexion deformity and muscle
contracture was present in 33(2%) and 5(0.3%) patients,
respectively. Joint replacement surgery was performed in 11
patients while 2 underwent serial plaster casting. There were 73
(40%) patients with joint disability who were using orthopedic
appliances of whom 15 (21%) were wheelchair bound, while 58
(79%) patients were using either walker/crutches or walking
sticks/canes. Only 93 (6%) registered patients were on regular
physiotherapy.
Treatment Details
There were 1026 (69%) patients who received only blood com-
ponents for treatment of any bleeding episode while the
remaining 464 (31%) were treated with blood components in
combination with factor concentrates. The average dose of
plasma-derived factor VIII or IX concentrate in combination
therapy was 10 to 15 IU /kg within 5 to 7 days. Clotting factor
concentrates in vWD were used on an average of 1 vial of 500
IU human coagulation factor VIII (FVIII) and 1200 IU human
vWF per week. Clotting factor concentrates are usually given
on the initial 1 to 2 days of bleed together with blood compo-
nents. There were 349 (41%), 45 (31%), 66 (3.5%), and 4
(18%) patients with HA, HB, vWD, and suspected carrier
females HA/vWD with on combination therapy respectively.
Only 7 (0.5%) patients (5 patients with HA and 2 patients with
vWD) have received treatment with clotting factor
concentrates.
As shown in Table 3, FFP (47%) and CP (43%) were the
most commonly transfused blood component and patients with
HA were the highest consumers. Although CS is only indicated
in HB, it was transfused in patients with other IBD if the
respective center had exhausted its supply of required blood
components such as FFP and CP. Screening for transfusion
transmitted infections was performed on a yearly basis. Hepa-
titis C virus (28%) was the most prevalent transfusion trans-
mitted infection as shown in Table 3. Patients with PFDs (38%)
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Figure 1. Patients in different age groups (n ¼ 1497). HA indicates hemophilia A; HB, hemophilia B; vWD, von Willebrand disease; RBD, rare
bleeding disorders; PFD, platelet function defect.
4 Clinical and Applied Thrombosis/Hemostasis
T
a
b
le
2
.
D
em
o
gr
ap
h
ic
an
d
C
lin
ic
al
D
et
ai
ls
in
V
ar
io
u
s
IB
D
.a
B
le
e
d
in
g
D
is
o
rd
er
N
(M
/F
)
A
ge
,
Y
ea
rs
,
M
ea
n
(S
D
)
M
u
co
cu
ta
n
eo
u
s
B
le
ed
in
g,
n
(%
)
U
ri
n
ar
y,
n
(%
)
M
en
o
rr
h
ag
ia
,
n
(%
)
C
ir
cu
m
ci
si
o
n
,b
n
(%
)
G
as
tr
o
in
te
st
in
al
,
n
(%
)
M
u
sc
le
H
em
at
o
m
as
,
n
(%
)
H
em
ar
th
ro
si
s,
n
(%
)
In
tr
ac
ra
n
ia
l
B
le
ed
in
g,
n
(%
)
U
m
b
ili
ca
l
C
o
rd
,
n
(%
)
H
A
8
4
8
(8
4
8
/0
)
2
5
(1
2
)
6
2
2
(7
3
)
3
2
(4
)
–
2
9
8
(3
5
)
3
0
(4
)
2
5
(3
)
6
9
9
(8
2
)
5
0
(6
)
4
(1
)
M
ild
9
8
2
6
(1
1
)
7
0
(1
2
)
5
(1
5
)
–
3
2
(1
1
)
3
(1
0
)
1
(4
)
7
7
(1
1
)
2
(4
)
0
M
o
d
er
at
e
1
7
2
2
3
(1
2
)
1
3
1
(2
1
)
7
(2
2
)
–
6
7
(2
2
)
9
(3
0
)
8
(8
)
1
5
0
(2
2
)
2
1
(4
2
)
2
(5
0
)
Se
ve
re
2
3
3
2
2
(1
1
)
1
9
5
(3
1
)
5
(1
6
)
–
8
6
(2
9
)
9
(3
0
)
6
(2
4
)
2
0
4
(2
9
)
1
2
(2
4
)
2
(5
0
)
P
re
su
m
ed
H
A
c
2
2
6
2
7
(1
1
)
2
2
6
(3
6
)
1
5
(4
7
)
–
1
1
3
(3
8
)
9
(3
0
)
1
0
(4
0
)
2
6
8
(3
8
)
1
5
(3
0
)
0
H
B
1
4
4
(1
4
4
/0
)
2
5
(1
0
)
1
1
1
(7
7
)
3
(2
)
–
4
4
(3
1
)
6
(4
)
3
(2
)
1
2
2
(8
5
)
7
(5
)
1
(1
)
M
ild
2
3
2
4
(9
)
2
2
(2
0
)
0
–
6
(1
4
)
1
(1
7
)
1
(3
3
)
2
1
(1
7
)
0
0
M
o
d
er
at
e
3
1
2
3
(1
1
)
2
5
(2
3
)
0
–
1
1
(2
5
)
2
(3
3
)
2
(6
7
)
2
7
(2
2
)
2
(2
9
)
1
(1
0
0
)
Se
ve
re
2
3
2
5
(1
1
)
1
9
(1
7
)
1
(3
3
)
–
7
(1
6
)
1
(1
7
)
0
2
1
(1
7
)
1
(1
4
)
0
P
re
su
m
ed
H
B
c
4
5
2
7
(1
0
)
4
5
(4
0
)
2
(6
7
)
–
2
0
(4
5
)
2
(3
3
)
0
5
3
(4
3
)
4
(5
7
)
0
vW
D
1
7
2
(7
8
/9
4
)
2
5
(1
1
)
1
4
8
(8
6
)
8
(5
)
2
8
(3
0
)
3
4
(4
3
)
1
4
(8
)
5
(3
)
7
8
(4
5
)
1
1
(6
)
3
(2
)
T
yp
e
1
6
1
5
(7
)
6
(4
)
0
2
(7
)
0
0
0
3
(4
)
0
0
T
yp
e
2
8
2
4
(1
0
)
8
(6
)
2
(2
5
)
3
(1
1
)
0
0
0
2
(3
)
0
0
T
yp
e
3
2
2
5
(3
)
2
(1
)
0
0
0
0
0
2
(3
)
0
0
P
re
su
m
ed
vW
D
c
1
5
6
2
6
(1
1
)
1
3
2
(8
9
)
6
(7
5
)
2
3
(8
2
)
3
4
(1
0
0
)
1
4
(1
0
0
)
5
(1
0
0
)
7
1
(9
0
)
1
1
(1
0
0
)
3
(1
0
0
)
R
B
D
7
0
(4
6
/2
4
)
2
2
(1
0
)
5
7
(8
1
)
3
(4
)
2
(8
)
9
(2
0
)
3
(4
)
0
3
9
(5
6
)
3
(4
)
1
6
(2
3
)
P
FD
1
0
6
(6
5
/4
1
)
2
5
(9
)
9
7
(9
1
)
0
1
2
(2
9
)
1
8
(2
8
)
9
(8
)
0
2
6
(2
5
)
4
(4
)
1
(1
)
C
ar
ri
er
/
vW
D
d
2
2
(0
/2
2
)
2
4
(1
0
)
1
8
(8
2
)
0
6
(2
7
)
0
2
(9
)
0
5
(2
3
)
4
(1
8
)
0
U
n
d
ia
gn
o
se
d
e
1
3
5
(1
1
5
/2
0
)
2
4
(1
1
)
9
1
(6
7
)
4
(3
)
5
(2
5
)
1
7
(1
5
)
2
(2
)
4
(3
)
6
6
(4
9
)
1
(1
)
3
(2
)
T
o
ta
l
1
4
9
7
(1
2
9
6
/2
0
1
)
2
5
(1
1
)
1
1
4
4
(7
6
)
5
0
(3
)
5
4
(2
7
)
4
2
0
(3
2
)
6
6
(4
)
3
7
(2
)
1
0
3
5
(6
9
)
8
0
(5
)
2
8
(2
)
A
b
b
re
vi
at
io
n
s:
F,
fe
m
al
e;
H
A
,
h
em
o
p
h
ili
a
A
;
H
B
,
h
em
o
p
h
ili
a
B
;
IB
D
,
in
h
er
it
ed
b
le
ed
in
g
d
is
o
rd
er
s;
M
,
m
al
e;
P
FD
,
p
la
te
le
t
fu
n
ct
io
n
d
ef
ec
t;
R
B
D
,
ra
re
b
le
ed
in
g
d
is
o
rd
er
s;
SD
,
st
an
d
ar
d
d
ev
ia
ti
o
n
;
vW
D
,
vo
n
W
ill
eb
ra
n
d
d
is
ea
se
.
a
n
¼
1
4
9
7
.
b
C
ir
cu
m
ci
si
o
n
w
as
p
er
fo
rm
ed
in
n
¼
4
8
7
p
at
ie
n
ts
.
c
P
re
se
n
ce
o
f
cl
in
ic
al
ly
si
gn
ifi
ca
n
t
b
le
ed
in
g
an
d
in
ad
eq
u
at
e
la
b
o
ra
to
ry
in
ve
st
ig
at
io
n
s
re
sp
o
n
d
in
g
to
tr
ea
tm
en
t
w
it
h
d
ef
ic
ie
n
t
cl
o
tt
in
g
fa
ct
o
r
co
n
ce
n
tr
at
es
o
r
b
lo
o
d
co
m
p
o
n
en
t
co
m
p
ri
si
n
g
th
e
m
is
si
n
g
fa
ct
o
r.
d
Su
sp
ec
te
d
ca
rr
ie
rs
fo
r
H
A
o
r
vW
D
;
n
o
co
n
fir
m
at
o
ry
te
st
s
p
er
fo
rm
ed
.
e
P
re
se
n
ce
o
f
cl
in
ic
al
ly
si
gn
ifi
ca
n
t
b
le
ed
in
g
in
th
e
ab
se
n
ce
o
f
la
b
o
ra
to
ry
in
ve
st
ig
at
io
n
s.
5
have the highest frequency of HCV followed by an equal pre-
valence of HCV in HA and HB (30%).
In HA, inhibitor screening was performed in 82 (10%)
patients (37 severe, 19 moderate, 8 mild, and 18 patients with
unknown severity), while in HB there were 17 (12%) patients
(6 severe, 5 moderate, 5 mild, and 1 patient with unknown
severity) screened for the presence of inhibitors. Inhibitors
were detected in 22 (27%) patients with HA (10 patients with
severe HA, 5 with moderate HA, and 7 patients with unknown
severity) and 2 (12%) patients with moderate HB.
Discussion
Our survey identified that approximately 1500 patients with
IBD were actively receiving care at 8 hemophilia treatment
centers in Pakistan. With a high predominance of patients in
early adulthood, it is apparent that very few survive past the age
of 45 years. We report the frequencies of HA, vWD, HB, PFD,
and RBDs as 57%, 12%, 10%, 7%, and 2%, respectively.
Severe hemophilia (44%) was the most common. Literature
review from southern Pakistan also revealed HA (37%) and
vWD (18%) being the most frequent followed by PFDs
(13%), HB (9%), and RBD (3%).5 A study from Iran8 reported
frequencies of HA (52%), HB (17%), vWD (9%), and PFDs
(7%) that was comparable to our population. In Brazil,9 the
frequency of HA (63%), HB (12%), and vWD (21%) is
reported to be higher in comparison to our population. In an
Indian population,10 HA (42%) and PFDs (39%) was more
common than HB (5%) and vWD (9%). In PFDs, GTT was
more common than BSS, similar to that reported in our study.
We have shown an increased prevalence of HA, similar to
the registries published by other developing countries. How-
ever, this is contrary to the data shown by the developed
nations where diagnosis of vWD is almost equivalent to HA
or showing a rising trend.11,12 There are significant limita-
tions in the diagnosis of vWD in developing countries due
to the high cost and lack of availability of diagnostic tests
in majority of our centers. A similar diagnostic dilemma has
also been reported from India.13
The frequency of RBD in our study was 5% and FV defi-
ciency (28%) was the most common, while previous studies
from southern Pakistan report FVII deficiency5,6 to be the most
common. A study performed in Iran8 reported a higher fre-
quency of RBD (16%) with combined FV and VIII deficiency
being predominant. The most common RBD in India10 was FX
deficiency while afibrinogenemia and factor VII deficiency is
common in Egypt and Brazil, respectively.9,14
Screening and diagnostic facilities were available for 87%
hemophilia treatment centers. However, specialized laboratory
tests including inhibitor workup was only available in 1 hemo-
philia treatment center. There was a significant subset (45%) of
patients who either remained undiagnosed or were managed
Table 3. Utilization of Blood Components and Transfusion Transmitted Infections in Patients With IBD.
Diagnosis
Blood Components, n ¼ 1497 TTI, n ¼ 1288
FFP, n (%) CP, n (%) CS, n (%) Platelets, n (%)
No. of Patients
Screened, n HBV, n (%)
HCV,
n (%)
HIV,
n (%)
Coinfection,
n (%)
HA 397 (56) 470 (74) 2 (2) – 745 3 (0.4) 223 (30) 1 (0.1) 5a (1)
HB 54 (8) – 87 (92) – 129 1 (1) 38 (30) 0 0
vWD 90 (13) 94 (15) 1 (1) 3 (3) 146 1 (1) 38 (26) 0 0
RBD 70 (9) 33 (5) 66 (70) – 59 0 15 (25) 0 0
PFD 9 (1) – 0 99 (87) 84 2 (2) 30 (36) 0 0
Carrier/vWD 15 (2) 16 (2) 0 0 22 2 (9) 3 (14) 0 0
Undiagnosed 85 (12) 15 (2) 1 (1) 10 (9) 103 1 (1) 8 (8) 0 1a (1)
Total 708 (47) 639 (43) 95 (13) 114 (8) 1288 10 (1) 355 (28) 1 (0.01) 6 (0.5)
Abbreviations: CP, cryoprecipitate; CS, cryosupernatant; FFP, fresh frozen plasma; HA, hemophilia A; HB, hemophilia B; HBV, hepatitis B virus; HCV, hepatitis C
virus; HIV, human immunodeficiency virus; IBD, inherited bleeding disorders; PFD, platelet function defect; RBD, rare bleeding disorders; TTI, transfusion
transmitted infections; vWD, von Willebrand disease.
aIn the HA group, n ¼ 4 had coinfection with HCV and HBV, and 1 patient had coinfection with HIV and HCV, while in the 1 patient in the undiagnosed category
had coinfection with HBV and HCV.
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Figure 2. Annual bleeding episodes (n ¼ 1413). HA indicates
hemophilia A; HB, hemophilia B; vWD, von Willebrand disease; RBD,
rare bleeding disorders; PFD, platelet function defect.
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according to clinical diagnosis. Diagnostic facilities were at its
worst in the hemophilia treatment center located in Quetta
where 68% remained undiagnosed compared to Karachi (3%)
where diagnostic facilities are easily available. Reason behind
barriers to diagnosis was lack of diagnostic facility at the hemo-
philia treatment center and surrounding area, expense of diag-
nostic tests, lack of awareness of physicians, and infrequent
visits to the hemophilia treatment center in the off timings.
These challenges have also been previously identified.15 The
optimal solution would be setting up a diagnostic laboratory in
each province with subsidized charges to cater its own treat-
ment centers. This will be beneficial to the patients in terms of
affordability. We aim to hold continuing medical education on
bleeding disorders for increasing education of physicians as
well as public awareness programs for patients and their
families.
In case of bleeding in undiagnosed patients, FFP is usually
the first choice to resolve the bleed; if persistent, platelets are
transfused as a second line therapy. Treatment facilities were
variable with plasma therapy availability in 100% hemophilia
treatment centers followed by platelets, CP, and CS in 87%
hemophilia treatment centers. All hemophilia treatment centers
had plasma-derived factors available all the time. However, it
was provided to patients only in life-threatening bleeding. Pain
management with acetaminophen, diclofenac sodium, and tra-
madol was offered at all hemophilia treatment centers while
management of inhibitors was available at 2 hemophilia treat-
ment centers with either FEIBA or recombinant factor VIIa,
depending on its availability. Immune tolerance therapy was
not available at any center.
Diagnostic facility for viral screening such as HIV, HBV,
and HCV was available in 100% hemophilia treatment centers.
Since 372 (29%) transfused patients acquired viral hepatitis, it
is of utmost importance to transfuse patients with recombinant
factors rather than blood or blood products. Transfusion trans-
mitted infections were less common in neighboring country
Iran, where HCV and HBV was found in 15% and 0.2%
patients, respectively, while HIV was absent.16 This may be
because of locally produced low-cost clotting factors in Iran.
Similarly, Syria had lesser frequency of HBV (0.5%) and HCV
(20%) compared to Pakistan.17
Inhibitor screening was performed only in those patients in
whom bleeding failed to resolve 24 hours after beginning ther-
apy with clotting factor concentrates and CP. Inhibitors were
present in 27% patients with HA and 12% patients with HB.
This is higher compared to that reported from Brazil (HA, 10%
and HB, 2%),9 Turkey (HA, 10%),18 and China (HA, 4%)19 but
lower than that reported from India (HA, 39%).20 We reported
inhibitors in moderate form of HA. This is not surprising as this
has been reported by Wight et al and Paschal et al.21,22
Physiotherapy was available in 50% of hemophilia treat-
ment centers. Social, psychological, or genetic counseling ser-
vices were not provided in any hemophilia treatment center.
Emergency care for bleeds was only available for 24 hours in
Karachi, while patients in the remaining localities went to the
emergency services present at the tertiary care hospitals where
the level of care depended on the level of awareness for IBD
and availability of clotting factor concentrates or blood com-
ponents. Prophylaxis and home treatment were not available to
any patient.
There are several limitations in this study. Due to the manual
collection of retrospective data, there is a possibility of errors
that include missing information. Around 20% to 30% of data
were not reported either because tests were not performed or
because the reports were missing from patients’ medical record
files. Since this is the initiation of a registry, mortality data
were not available at the time of data collection. Treatment
details of transfusion transmitted infections and factor concen-
trate utilization per annum was also missing. There is a pro-
pensity for the under representation of patients affected with
vWD, since only patients with clinically significant bleeding
seek referral for diagnosis and management. Lack of further
sub typing of vWD due to the lack of diagnostic facilities in
various treatment centers has made it difficult to ascertain the
commonest subtype of vWD in our cohort. Flexion deformity,
muscle contracture, and physiotherapy details were documen-
ted for few patients despite lack of regular prophylaxis. In
treatment centers, there is a lack of electronic medical charts,
and the data were entered manually in medical files. Hence,
lack of documentation may be a possible reason.
Conclusion
This survey reports a detailed registry of IBD and their man-
agement at a not-for-profit organization in a developing coun-
try to form the basis for planning development and research.
The next daunting task will be to diagnose undiagnosed
patients or those being treated on the basis on clinical diagno-
sis. Also, it is important to acquire a centrally operated web-
based registry in each hemophilia treatment center and to
update the registry on a yearly basis. The regular, systematic
collection of data will give a clearer picture of the burden of
IBD in Pakistan and help us in planning care and evaluate
effective use of resources in an already resource limited setting.
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